Menu

Blog

Page 3064

Nov 22, 2022

Population scientist identifies rapid rise in cervical cancer in millennial women

Posted by in categories: biotech/medical, health

MUSC Hollings Cancer Center researcher Ashish Deshmukh, Ph.D., has identified a dramatic recent rise in cervical cancer incidence among women in their early 30s. This work was published Nov. 21 in the Journal of the American Medical Association (JAMA).

Cervical cancer is mostly related to human papillomavirus (HPV), and has made this cancer preventable. Yet, it is estimated that over 14,000 new cases will be diagnosed this year and more than 4,000 deaths will be attributed to .

“HPV is a group of over 200 viruses. At least 14 high-risk HPV types can cause several types of cancers, including cervical, anal and head and neck cancers. In the era of the overall decline in cancer incidence, cancers caused by HPV are unfortunately rising,” said Deshmukh, an associate professor in the Department of Public Health Sciences at MUSC.

Nov 22, 2022

Evaluating cell-free DNA-based blood tests for early detection of multiple cancers

Posted by in category: biotech/medical

In a recent study published in Cancer Cell, researchers assessed several approaches for a circulating cell-free deoxyribonucleic acid (cfDNA)-based multi-cancer early detection (MCED) test. Defining the clinical limit of detection (LOD) based on circulating tumor allele fraction (cTAF) enables the comparison of different approaches.

An MCED test is a blood test that helps early detection of a shared cancer signal across multiple cancers using blood samples. Currently, available MCED tests have a low false-positive rate of less than 1%.

Nov 22, 2022

DARPA is playing both sides of the ball with both offensive and defensive hypersonics

Posted by in category: futurism

HAWC and Glide Breaker are DARPA’s offensive and defensive hypersonic programs, respectively, and their program managers discuss what’s been done and what’s next.

Nov 22, 2022

Lejjy Gafour is Revolutionizing Food

Posted by in categories: food, innovation

Discover breaking news, innovative companies and an active community of investors all in one place.

Nov 22, 2022

Ownership of AI-Generated Code Hotly Disputed

Posted by in category: robotics/AI

GitHub Copilot dubs itself as an “AI pair programmer” for software developers, automatically suggesting code in real time. According to GitHub, Copilot is “powered by Codex, a generative pretrained AI model created by OpenAI” and has been trained on “natural language text and source code from publicly available sources, including code in public repositories on GitHub.”

However, a class-action lawsuit filed against GitHub Copilot, its parent company Microsoft, and OpenAI claims open-source software piracy and violations of open-source licenses. Specifically, the lawsuit states that code generated by Copilot does not include any attribution to the original author of the code, copyright notices, or a copy of the license, which most open-source licenses require.

“The spirit of open source is not just a space where people want to keep it open,” says Sal Kimmich, an open-source developer advocate at Sonatype, machine-learning engineer, and open-source contributor and maintainer. “We have developed processes in order to keep open source secure, and that requires traceability, observability, and verification. Copilot is obscuring the original provenance of those [code] snippets.”

Nov 22, 2022

How much would you pay to see a woolly mammoth?

Posted by in categories: biotech/medical, existential risks

We spoke to Sara Ord, director of species restoration at Colossal, the world’s first “de-extinction” company, about its big ambitions.

Nov 22, 2022

GPT-4 is Almost Here, And it Looks Better than Anything Else

Posted by in categories: futurism, robotics/AI

In May 2020, AI research laboratory OpenAI unveiled the largest neural network ever created—GPT-3—in a paper titled, ‘Language Models are Few Shot Learners’. The researchers released a beta API for users to toy with the system, giving birth to the new hype of generative AI.

People were generating eccentric results. The new language model could transform the description of a web page into the corresponding code. It emulates the human narrative, by either writing customised poetry or turning into a philosopher—predicting the true meaning of life. There’s nothing that the model can’t do. But there’s also a lot it can’t undo.

As GPT-3 isn’t that big of a deal for some, the name remains a bit ambiguous. The model could be a fraction of the futuristic bigger models that are yet to come.

Nov 22, 2022

J. Robert Oppenheimer: “I am become Death, the destroyer of worlds.”

Posted by in category: military

J. Robert Oppenheimer speaks those famous words.

This video was posted on the 66th anniversary of the atomic bombing of Hiroshima.

Nov 22, 2022

Dr. David Sinclair

Posted by in categories: biological, genetics, life extension

Harvard University geneticist Dr. David Sinclair’s lab is developing a cheek swab test kit so that you can check your biological age at home. You then get updates on how to slow down and reverse your aging.


Find out how fast you’re aging with Tally Health. The future of healthy aging is here.

Nov 21, 2022

Immunotherapy can be critical to treatment of different types of cancer, claim research

Posted by in category: biotech/medical

Washington, Scientists have found a novel immunotherapy that could bolster the effectiveness of cancer treatment, according to a study. Rather than rally T cells against cancer, scientists have used different human immune cells called natural killer (NK) cells as a novel means to fight cancer, according to a study.

The team of scientists at Albert Einstein College of Medicine described findings that could boost the impact of immune-checkpoint therapy, the study said. Findings have been published in The Journal of Clinical Investigation (JCI).

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumour cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10 per cent to 30 per cent of treated patients experience long-term improvement, the study said.